{"prompt": "['Date: June 30, 2020', 'Version: 8.0', 'Page: 31 of 52', '8.7', 'Treatment compliance', 'Upon receipt of the study drug, the investigator, or a responsible party designated by the', 'investigator, will conduct an inventory of the supplies and verify that study drug supplies are', 'received intact and in the correct amounts. A full drug accountability log will be maintained at the', 'study site at all times. All discrepancies must be accounted for and documented.', 'Subjects will be expected to return all unused study drug and empty containers to the site at each', 'clinic visit, and the number of capsules dispensed and returned will be documented by study staff.', 'The study personnel will account for all drugs dispensed and returned. All unused supplies of SYN-', '010 and other investigational agents will be destroyed appropriately and according to institutional', 'policies. Destruction will be documented in the Drug Accountability Record form.', 'Subjects who are not compliant with treatment protocol, including laboratory evaluations, will be', 'subject to withdrawal from the study at the discretion of the investigator.', '8.8', 'Prior and concomitant therapy', 'Any prior or concomitant therapy that the patient may be taking and may be necessary for the', \"patient's welfare taken within two weeks prior to the start of the study and during the study must\", \"be recorded in the patient's source documentation and in the CRF (including start/stop dates, dose\", 'frequency, route of administration, and indication).', 'The patient may be on a stable, continuous regimen of fiber, or probiotics one month before the', 'Screening Visit; however, he/she must maintain a stable dose regimen through Week 12.', 'Additionally, certain drugs used for the treatment of IBS (e.g. low dose tricyclic antidepressants) may', 'be allowed at the discretion of the Medical Monitor provided the patient remains on a stable dose', 'for one month prior to the Screening Visit and throughout the study with the exception of', 'tegaserod, lubiprostone, linaclotide, metoclopramide, prucalopride, domperidone, plecanatide,', 'CandiBactin, Atrantil, Allimax/Allimed within 2 weeks prior to the Screening Visit or antibiotics', 'within 2 months prior to the Screening Visit.', 'Rescue medication will be allowed for severe constipation (i.e. when symptoms become', 'intolerable). For guidance purposes for this protocol, intolerable symptoms may be when a subject', 'has not had a complete spontaneous bowel movement (CSBM) in the preceding three days with an', 'abdominal pain score of 6 on an 11-point (0-10) scale each day during that time period. However,', 'intolerability is ultimately a subjective judgment, and principal investigators and their patients make', 'the final decision regarding what is intolerable and requires use of the rescue medication. For the', 'Randomization Visit only, rescue medication will not be allowed the day before, the day of, or the', 'calendar day after the Randomization Visit. If rescue medication is taken during this time, it must be', 'recorded as a protocol deviation and the subject should not be randomized. The use of protocol-', 'specified rescue medication and non-protocol-specified laxatives will be recorded in the subject', 'record.', 'Permitted rescue medications include bisacodyl, magnesium citrate, magnesium hydroxide, and', 'lactulose. Dosage and frequency should be followed according to package insert on rescue', 'medication and should not exceed recommended doses as approved by package insert.']['Date: June 30, 2020', 'Version: 8.0', 'Page: 32 of 52', '9. Procedures and variables', '9.1', 'Schedule of assessments', 'Table 1: Schedule of assessments', 'X = required; O = only if directed by symptoms or reported AE; ET = early termination', 'Visit No.', '1', '--', '2', '3', '4', '5', 'EOS', 'Type', 'Screen', 'Pre-treatment', 'Randomize', 'Call/Visit', 'Days', '-17 to -14', '-17 to -1', '1', '28', '56', '84 or ET', '85', 'Window (Days)', '--', '--', '--', '+5', '+5', '+5', '+1', 'Participant Information', 'Informed Consent1', 'X', '--', '--', '--', '--', '--', '--', 'Inclusion/Exclusion\u00b9', 'X', '--', '--', '--', '--', '--', '--', 'IBS-C Criteria (ROME IV)', 'X', '- -', '- -', '--', '--', '--', '--', 'Demographics\u00b2', 'X', '--', '--', '--', '--', '--', '--', 'Medical History\u00b3', 'X', '--', 'X', '--', '--', '--', '--', 'Prior/Concomitant', 'X', '--', 'X', 'X', 'X', 'X', 'X', 'Medications', 'Diary compliance/', 'X', 'X', '--', '--', '--', '--', 'eligibility to randomize4', 'Physical', 'Physical Exam5', 'X', '--', 'X', 'O', 'O', 'X', 'O', 'Vital Signs', 'X', 'X', 'X', 'X', 'X', 'O', '12-Lead ECG7', 'X', '--', '--', '--', 'X', '--', 'Drug Dispensing', 'Drug Dispensing', '--', 'X', 'X', 'X', 'Accountability/Returns', '--', '--', 'X', 'X', 'X', '--', 'Adverse Events', 'AEs', '--', '--', 'X', 'X', 'X', 'X', 'X', 'Blood Samples', 'Clinical Chemistry (CMP)', 'X', '--', 'X', 'X', 'X', '--', 'Lipid Panel', 'X', 'X', 'Cytokine Analysis', '--', '--', 'X', 'X', '--', 'X', 'Hematology', 'X', '--', '--', 'X', 'Serum Pregnancy8', 'X', '--', '--', '--', '--', '--', '--', 'Creatine Kinase (CK)', 'X', '--', '--', 'O', 'O', 'O', 'O', 'Urine Samples']\n\n###\n\n", "completion": "END"}